Summary Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

3. Competitive Intelligence Analysis for Lipodystrophy Syndrome 4. Lipodystrophy Syndrome Market Overview at a Glance 5. Lipodystrophy Syndrome: Disease Background and Overview 6.

Goldman Sachs launched its coverage of Viking Therapeutics (NASDAQ:VKTX) with a Neutral recommendation and a $30 per share target on Tuesday, arguing that competitive headwinds in the weight loss ...